11 March 2021 
navy.png
BIOS HEALTH PARTNERS WITH UK'S LEADING HEART AND LUNG HOSPITAL IN SEEKING OUT THE RISK FACTORS FOR CHRONIC CARDIORESPIRATORY DISEASES

Cambridge, UK – 11 March 2021 – BIOS Health has partnered with the Royal Papworth Hospital in Cambridge, the UK's leading heart and lung hospital, and the Sheffield Teaching Hospitals NHS Foundation Trust in a study seeking out the risk factors for pulmonary arterial hypertension. BIOS’ remote patient monitoring technology will enable the collection of continuous health data from their patients and AI-powered insights on patterns in their cardiac and mobility data. 

Pulmonary arterial hypertension (PAH), is a chronic cardiorespiratory condition caused by changes within the arteries within the lungs primarily found in younger people. It results in high blood pressure, and in severe cases can lead to heart failure. Whilst some patients who suffer from PAH appear to have a genetic predisposition, in many the cause of the disease is unknown. The National Cohort Study of Idiopathic and Heritable PAH aims to better understand the causes and potential treatments for this condition by studying a cohort of patients with the disease over a number of years. 

BIOS will track the mobility and cardiac activity of a number of patients taking part in the study using wearable devices. This means a large quantity of data can be collected as the trial participant goes about their daily life. BIOS’ machine learning software will analyse this data to give an overview of their mobility, fitness and heart performance over time and how patterns in the data relate to patients’ individual forms of PAH and their long term outcomes. 

The company's aim in future studies is to combine data collected from wearables with BIOS’ unique neural technology, that can understand and sequence neural code, in order to develop AI-powered neural treatments for chronic disease. Neural interfaces can be used to form a direct connection with the neurons around the heart and other organs, which offers a whole new class of treatments for cardiovascular disease. In the majority of cardiac conditions, the role of the nervous system is known to be a major factor in the disease but is poorly understood. For cardiac medicine as a whole, if we develop the understanding to decode and encode these neural signals in real time, we can treat chronic illnesses in an effective, automated, and personalised way. 

Emil Hewage, CEO & Co-founder of BIOS said: “Through our partnership with the Royal Papworth Hospital and the Sheffield Teaching Hospitals NHS Foundation Trust, BIOS can develop an understanding of the impacts and risk factors of chronic cardiorespiratory diseases on health which could result in life-changing treatments. However, the COVID-19 pandemic has made it more important to be able to carry out studies like this remotely, without sacrificing the quality of data gathered from patients. The BIOS remote monitoring platform can support clinicians in tracking health metrics and  patient surveys in one platform powered by our own  datasets and biomarkers identified through our extensive neural research.  At a time when COVID-19 is highlighting the fragility of health for those with chronic diseases, we are proud to be launching new initiatives that have the potential to create vastly more powerful treatments and preventions, and therefore reduce the number of people at high risk in the long-term.” 

Mark Toshner MD MRCP, University Lecturer at the University of Cambridge School of Clinical Medicine and Honorary Consultant Papworth Hospital NHS Trust said: “The events of the last year have accelerated the need for remote technology in the daily management of patients. We are delighted to be partnering with BIOS to pioneer patient-centred care that will allow us to improve the experience and outcomes of living with chronic cardiorespiratory diseases.”


About BIOS Health

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. The human nervous system carries vast quantities of data and scientists have long known that faulty signals in the nervous system play a key role in driving chronic diseases. By understanding and correcting these signals in real time, BIOS can treat chronic illnesses in an effective, automated, and personalised way. BIOS has leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. BIOS’ neural code is built on the world’s largest proprietary neural data set and is already in use clinically to enhance data from wearables used in remote chronic disease care. In December 2020, BIOS launched its pioneering Autonomic Therapy Initiative (BIOS ATI), which will see the company work with world leading partners to deliver a new class of treatments for heart disease using AI-powered neural interfaces

Co-founded by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology, and medicine. The combined experience of the BIOS team extends to over 300 peer-reviewed publications, 10+ First of kind medical devices and 6k+ clinical procedures.
 
Media contact

Gabriella Jeakins
BIOS 
Marketing & Communications Associate
gabriella@bios.health